A budget impact analysis of 15- or 20- valent pneumococcal conjugate vaccine use in all US adults ag...
A budget impact analysis of 15- or 20- valent pneumococcal conjugate vaccine use in all US adults aged 50-64 years old compared to those with high-risk conditions from US payer perspective
About this item
Full title
Author / Creator
Publisher
England: BioMed Central Ltd
Journal title
Language
English
Formats
Publication information
Publisher
England: BioMed Central Ltd
Subjects
More information
Scope and Contents
Contents
In 2023, the US CDC recommended 20-valent pneumococcal conjugate vaccine (PCV20) or 15-valent pneumococcal conjugate vaccine (PCV15) followed by 23-valent pneumococcal polysaccharide vaccine (PPSV23) for all adults aged 65-years and older and those aged 19-64 years old with chronic conditions. However, there is substantial pneumococcal disease burd...
Alternative Titles
Full title
A budget impact analysis of 15- or 20- valent pneumococcal conjugate vaccine use in all US adults aged 50-64 years old compared to those with high-risk conditions from US payer perspective
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_f9b1779bb41e4f2b8167575c26877df8
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_f9b1779bb41e4f2b8167575c26877df8
Other Identifiers
ISSN
1471-2458
E-ISSN
1471-2458
DOI
10.1186/s12889-025-22827-9
